Lipid nanocarriers for delivery of poorly soluble and poorly permeable drugs

Solid Lipid Nanoparticles for Drug Delivery: Pharmacological and Biopharmaceutical Aspects

“…Therefore, pharmaceutical chemists will always have to deal with the PK/PD & toxicity balance, and the aqueous solubility will remain to be a critical factor in drug discovery. Proof of this is that, to date, approximately 39% of the marketed drugs (Benet, 2013) and 60% of the new chemical entities (Kovačević, 2020) belong to the biopharmaceutical categories that group low solubility drugs (i.e., BCS classes 2 and 4).…”

Lipid nanoparticle-based formulations for high-performance dentistry applications

“…124 Among different nanocarrier systems, lipid-based nanostructures represent one of the most potential colloidal systems as the carrier for chemotherapeutic agents. 81,[125][126][127][128][129][130][131] Some of the lipid NPs-based formulations are either in clinical trials or a few have already been commercialized for cancer targeting. 132,133 For dental or oral applications, the most commonly known mode of drug administration includes oral gel, rinses, mucoadhesive patches, and localized injection at the diseased site.…”

Functionalized Liposome and Albumin-Based Systems as Carriers for Poorly Water-Soluble Anticancer Drugs: An Updated Review

“…Poor water solubility is a common problem in the new drug candidates, caused by a high lipophilicity, large molecular weight, and high logP values [ 12 , 13 ]. About 40% of new drugs with market approval and 60% of new chemical entities coming directly from chemical synthesis are poorly water-soluble [ 13 , 14 ].…”

“…New, poorly soluble drug candidates are limited in their real application, because low solubility reduces the dissolution rate and oral bioavailability, creating a challenge in pharmaceutical development [ 14 , 15 , 16 , 17 ]. Moreover, many new drugs fail to meet appropriate absorption, distribution, metabolism, and excretion (ADME) properties, due to the low dissolution rate, resulting in low blood levels [ 12 ]. In order to obtain an ideal molecule, besides the pharmacological activity, it is necessary to have appropriate physicochemical characteristics, such as low toxicity, associated with selectivity to the therapeutic target, slow metabolism, and solubility in water [ 15 ].…”

“…In order to obtain an ideal molecule, besides the pharmacological activity, it is necessary to have appropriate physicochemical characteristics, such as low toxicity, associated with selectivity to the therapeutic target, slow metabolism, and solubility in water [ 15 ]. Consequently, research is focused on the development of more effective and versatile approaches, comprising chemical and physical modifications, to improve the bioavailability of hydrophobic drugs [ 12 ]. To enhance bioavailability and absorption, an increase in the dissolution rate is required, which is possible with nanonization, by increasing the particles’ surface area and saturation solubility.…”